Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;89(2):633-640.
doi: 10.3233/JAD-220026.

Interactive Effects of Pulse Pressure and Tau Imaging on Longitudinal Cognition

Alexandra J Weigand  1 , Alyssa J Macomber  2 , Kayla S Walker  3 , Lauren Edwards  1 , Kelsey R Thomas  2   4 , Katherine J Bangen  2   4 , Daniel A Nation  5 , Mark W Bondi  2   4 ; Alzheimer’s Disease Neuroimaging Initiative
Affiliations

Interactive Effects of Pulse Pressure and Tau Imaging on Longitudinal Cognition

Alexandra J Weigand et al. J Alzheimers Dis. 2022.

Abstract

Background: Studies have demonstrated that both tau and cardiovascular risk are associated with cognitive decline, but the possible synergistic effects of these pathologic markers remain unclear.

Objective: To explore the interaction of AD biomarkers with a specific vascular risk marker (pulse pressure) on longitudinal cognition.

Methods: Participants included 139 older adults from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Biomarkers of tau, amyloid-β (Aβ), and vascular risk (pulse pressure) were assessed. Neuropsychological assessment provided memory, language, and executive function domain composite scores at baseline and 1-year follow-up. Multiple linear regression examined interactive effects of pulse pressure with tau PET independent of Aβ PET and Aβ PET independent of tau PET on baseline and 1-year cognitive outcomes.

Results: The interaction between pulse pressure and tau PET significantly predicted 1-year memory performance such that the combined effect of high pulse pressure and high tau PET levels was associated with lower memory at follow-up but not at baseline. In contrast, Aβ PET did not significantly interact with pulse pressure to predict baseline or 1-year outcomes in any cognitive domain. Main effects revealed a significant effect of tau PET on memory, and no significant effects of Aβ PET or pulse pressure on any cognitive domain.

Conclusion: Results indicate that tau and an indirect marker of arterial stiffening (pulse pressure) may synergistically contribute to memory decline, whereas Aβ may have a lesser role in predicting cognitive progression. Tau and vascular pathology (particularly in combination) may represent valuable targets for interventions intended to slow cognitive decline.

Keywords: Amyloid PET; cardiovascular risk; cognition; executive function; memory; pulse pressure; tau PET.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTERST/DISCLOSURE STATEMENT

Dr. Mark Bondi receives royalties from Oxford University Press. All other authors report no disclosures relevant to the manuscript.

Figures

Figure 1.
Figure 1.
Scatterplots depicting the association between Braak stage III/IV tau PET and memory performance at year 1 for participants with high (red) and low (navy) pulse pressure. Pulse pressure categories were determined by median split. All variables have undergone Box-Cox transformation to improve normality. PET = positron emission tomography. PP = pulse pressure.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rubin R Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered. JAMA. 2021;326(6):469–472. doi:10.1001/jama.2021.11558 - DOI - PubMed
    1. Castellani RJ, Smith MA. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’. J Pathol. 2011;224(2):147–152. doi:10.1002/path.2885 - DOI - PubMed
    1. Castellani RJ, Plascencia-Villa G, Perry G. The amyloid cascade and Alzheimer’s disease therapeutics: theory versus observation. Lab Invest. 2019;99(7):958–970. doi:10.1038/s41374-019-0231-z - DOI - PubMed
    1. Fillit H, Green A. Aducanumab and the FDA - where are we now?. Nat Rev Neurol. 2021;17(3):129–130. doi:10.1038/s41582-020-00454-9 - DOI - PubMed
    1. Schneider L. A resurrection of aducanumab for Alzheimer’s disease. Lancet Neurol. 2020;19(2):111–112. doi:10.1016/S1474-4422(19)30480-6 - DOI - PubMed

Publication types